News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
How risky is a second allogeneic stem cell transplantation? by Prof. Olaf Penack – IACH
Photo of Olaf Penack taken from haema-onko-cvk.charite.de
Aug 27, 2024, 23:15

How risky is a second allogeneic stem cell transplantation? by Prof. Olaf Penack – IACH

The International Academy for Clinical Hematology (IACH) shared on X:

“Hear the latest IACH News:

How risky is a second allogeneic stem cell transplantation? by Prof. Olaf Penack.”

Stem cell transplantation

Source: IACH/X

cancer Haematology IACH Olaf Penack OncoDaily Oncology
Special Coverage
Positive
Jun 7, 2025, 17:29
Fernanda Rivera: Grateful for All the Learning at CU Anschutz Medical Campus
Insight
Jun 7, 2025, 17:21
Elvina Almuradova: The Abscopal Effect Is Something I Haven’t Seen Materialize in Clinical Practice
Blog
Jun 7, 2025, 16:47
More People Are Living Longer With Lung Cancer - Lung Cancer Europe
Blog
Jun 7, 2025, 16:40
Nita Radhakrishnan: Sharing The Program of Midterm PHOCON 2025
Insight
Jun 7, 2025, 16:30
Goutham Sunny: Breakthroughs in Targeted Cancer Therapies
Career
Jun 7, 2025, 16:21
Jeff Dunn Has Been Honored with a Queensland Greats Award - Prostate Cancer Foundation of Australia
Blog
Jun 7, 2025, 16:07
Sebastian Szmit Spoke at the 55th Congress of Polish Society of Urology
Blog
Jun 7, 2025, 16:03
Mark Lawler: Talk About Shooting Yourself in the Foot - China Awaits in the Wings
Blog
Jun 7, 2025, 15:49
David Planchard: Post-ASCO Meeting with Gustave Roussy's Experts on June 17
Blog
Jun 7, 2025, 15:49
The Application Deadline For the M2ICOS Project is 15 June - European School of Oncology
Blog
Jun 7, 2025, 15:40
Carmen Monge-Montero: Language, Identity, Roots, Cancer … And a Podcast Recorded On The Go
Blog
Jun 7, 2025, 15:34
Evandro de Azambuja: Real-World Evidence Supporting APT Strategy in HER2+ Breast Cancer